<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117554">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01729169</url>
  </required_header>
  <id_info>
    <org_study_id>SarcoidosisPET</org_study_id>
    <nct_id>NCT01729169</nct_id>
  </id_info>
  <brief_title>Cardiac Sarcoidosis: FDG PET vs. Ga-DOTANOC PET</brief_title>
  <official_title>Diagnosing Cardiac Sarcoidosis Using FDG PET: Optimization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lars Christian Gormsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <authority>Denmark: The National Committee on Health Research Ethics</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnosing cardiac sarcoidosis has always been challenging: No single imaging modality has
      proved effective and cardiac biopsies have a very low sensitivity.
      18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) PET preceded by at least 12 hours of
      fasting has previously been demonstrated to have reasonable accuracy, however, in some
      patients physiological FDG uptake in the cardiac region hampers correct identification of
      sarcoid granulomas. Gallium Ga 68-DOTANOC is a conjugate of the somatostatin analogue
      Nal3-octreotide (NOC) and gallium Ga 68-labeled
      1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA). We aim to study
      whether 68Ga-DOTANOC has superior sensitivity and accuracy than 18-FDG PET in diagnosing
      cardiac sarcoidosis. In addition, we aim to compare 18-FDG PET preceded by 12 hours fasting
      with 18-FDG PET during somatostatin blockade of insulin mediated cardiac glucose uptake.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention:

        -  Study A: Subjects with biopsy proven sarcoidosis suspected of cardiac involvement
           (prone to arrhythmias, cardiac failure, unexplained dyspnea) are studied twice: 1)
           18-FDG PET preceded by 12 hours fasting and 2) 18-FDG PET performed during a 2 hour
           somatostatin blockade (300 microgram/hour)/Heparin infusion.

        -  Study B: Subjects with biopsy proven sarcoidosis suspected of cardiac involvement are
           studied twice: 1) 18-FDG PET preceded by 12 hours fasting and 2) 68Ga-DOTANOC PET
           preceded by at least 6 hours fasting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Crossover, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Cardiac sarcoidosis - Sensitivity</measure>
    <time_frame>01/01/2015</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ability to correctly identify patients with cardiac sarcoidosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial cardiac glucose uptake assessed by Cardiac SUV</measure>
    <time_frame>01/01/2015</time_frame>
    <safety_issue>No</safety_issue>
    <description>Semiquantitative assessment of myocardial glucose uptake, the Standardized Uptake Value (SUV). Expressed in g/ml.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Sarcoidosis</condition>
  <condition>Cardiac Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Sarcoidosis patients</arm_group_label>
    <description>Patients with biopsy proven sarcoidosis suspected of having cardiac sarcoidosis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with biopsy proven sarcoidosis suspected of having cardiac sarcoidosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven sarcoidosis

          -  Suspected cardiac sarcoidosis

        Exclusion Criteria:

          -  Ischemic heart disease

          -  Diabetes

          -  Cardiomyopathy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lars C Gormsen, MD PhD</last_name>
    <phone>+4578456205</phone>
    <email>lars.christian.gormsen@ki.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lars C Gormsen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 26, 2012</lastchanged_date>
  <firstreceived_date>November 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Christian Gormsen</investigator_full_name>
    <investigator_title>Consultant, MD PhD</investigator_title>
  </responsible_party>
  <keyword>Sarcoidosis</keyword>
  <keyword>Cardiac sarcoidosis</keyword>
  <keyword>18-FDG PET</keyword>
  <keyword>68Ga-DOTANOC PET</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
